首站-论文投稿智能助手
典型文献
Modified citrus pectin inhibits breast cancer development in mice by targeting tumor-associated macrophage survival and polarization in hypoxic microenvironment
文献摘要:
Large amounts of tumor-associated macrophages(TAM),which are predominately localized in hypoxia area of the tumor tissue,are associated with the malignant progression of the tumor.In the present study,we investigated the inhibitory effects of modified citrus pectin(MCP),a natural dietary polysaccharide,on the survival and polarization of TAM in relation to its inhibition on the growth and migration of breast cancer.M2 macrophages polarized from human monocyte THP-1 were chosen as a model for TAM.We showed that MCP(0.06%-1%)concentration-dependently suppressed the survival of TAM through inhibiting glucose uptake with a greater extent in hypoxia than in normoxia.Furthermore,MCP treatment decreased ROS level in TAM through its reducibility and inhibiting galectin-3 expression,leading to inhibition of glucose transporter-1 expression and glucose uptake.In addition,MCP suppressed M2-like polarization via inhibiting STAT3 phosphorylation.Moreover,the tumor-promoting effect of TAM could be restrained by MCP treatment as shown in human breast cancer MDA-MB-231 cells in vitro and in mouse breast cancer 4T1-luc orthotopic and metastasis models.In both tumor tissue and lung tissue of the mouse tumor models,the number of TAM was significantly decreased after MCP treatment.Taken together,MCP may be a promising agent for targeting TAM in tumor hypoxic microenvironment for breast cancer treatment.
文献关键词:
作者姓名:
Lei Wang;Lin Zhao;Fu-lian Gong;Chao Sun;Dan-dan Du;Xiao-xia Yang;Xiu-li Guo
作者机构:
Department of Pharmacology,Key Laboratory of Chemical Biology(Ministry of Education),School of Pharmaceutical Sciences,Shandong University,Ji-nan 250012,China
引用格式:
[1]Lei Wang;Lin Zhao;Fu-lian Gong;Chao Sun;Dan-dan Du;Xiao-xia Yang;Xiu-li Guo-.Modified citrus pectin inhibits breast cancer development in mice by targeting tumor-associated macrophage survival and polarization in hypoxic microenvironment)[J].中国药理学报(英文版),2022(06):1556-1567
A类:
B类:
Modified,citrus,pectin,inhibits,breast,cancer,development,mice,by,targeting,tumor,associated,survival,polarization,hypoxic,microenvironment,Large,amounts,macrophages,TAM,which,predominately,localized,hypoxia,area,tissue,malignant,progression,In,present,study,investigated,inhibitory,effects,modified,MCP,natural,dietary,polysaccharide,relation,inhibition,growth,migration,M2,polarized,from,human,monocyte,THP,were,chosen,We,showed,that,concentration,dependently,suppressed,through,inhibiting,glucose,uptake,greater,extent,than,normoxia,Furthermore,treatment,decreased,ROS,level,reducibility,galectin,expression,leading,transporter,addition,like,via,STAT3,phosphorylation,Moreover,promoting,could,restrained,shown,MB,cells,vitro,mouse,4T1,orthotopic,metastasis,models,both,lung,number,was,significantly,after,Taken,together,may,promising,agent
AB值:
0.528949
相似文献
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
Yanghe decoction(阳和汤)attenuated pain hypersensitivity induced by michigan cancer foundation-7 injection in rats with bone metastases from breast cancer by inhibiting transient receptor potential ankyrin 1
GONG Hui;LI Yang;FENG Lei;XIAO Yujie;HUANG Lizhong;MAO Dan;ZHANG Hui-Department of Medical Oncology,Hunan Academy of Traditional Chinese Medicine Affiliated Hospital,Changsha 410006,China;Department of Medical Oncology,Hunan Cancer Hospital,Changsha 410031,China;Department of Medical Oncology,Hunan University of Chinese Medicine,Changsha 410208,China;Department of Integrated Traditional Chinese and Western Medicine,the Second Xiangya Hospital,Central South University,Changsha 410011,Changsha,China;Department of Medical Oncology,Hainan Hospital of Traditional Chinese Medicine,Haikou 570203,China
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
Yi Xiao;Ding Ma;Yun-Song Yang;Fan Yang;Jia-Han Ding;Yue Gong;Lin Jiang;Li-Ping Ge;Song-Yang Wu;Qiang Yu;Qing Zhang;Francois Bertucci;Qiuzhuang Sun;Xin Hu;Da-Qiang Li;Zhi-Ming Shao;Yi-Zhou Jiang-Key Laboratory of Breast Cancer in Shanghai,Department of Breast Surgery,Fudan University Shanghai Cancer Center;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai,China;Human Phenome Institute,Fudan University,Shanghai,China;Department of Pathology,University of Texas Southwestern Medical Center,Dallas,TX,USA;Predictive Oncology team,Centre de Recherche en Cancérologie de Marseille(CRCM),INSERM UMR1068,CNRS UMR725,Aix-Marseille Université,Institut Paoli-Calmettes,Marseille,France;Department of Industrial Systems Engineering and Management,National University of Singapore,Singapore,Singapore
Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy
Xianbin Ma;Shaochen Yang;Tian Zhang;Shuo Wang;Qichao Yang;Yao Xiao;Xiaoxiao Shi;Peng Xue;Yuejun Kang;Gang Liu;Zhi-Jun Sun;Zhigang Xu-Key Laboratory of Luminescence Analysis and Molecular Sensing(Southwest University),Ministry of Education,School of Materials and Energy & Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices,Southwest University,Chongqing 400715,China;The State Key Laboratory Breeding Base of Basic Science of Stomatology(Hubei-MOST) & Key Laboratory of Oral Biomedicine,Ministry of Education,School and Hospital of Stomatology,Wuhan University,Wuhan 430079,China;State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine,School of Public Health,Xiamen University,Xiamen 361102,China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models
Ming Ji;Dongjie Wang;Songwen Lin;Chunyang Wang;Ling Li;Zhihui Zhang;Jing Jin;Deyu Wu;Yi Dong;Heng Xu;Duo Lu;Xiaoguang Chen-State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。